EOS Inc. is a Nevada-incorporated company specializing in distributing nutritional supplements and health products, primarily Ginsenoside supplements branded as "Bodywafer," with operations across Asia, including Taiwan and Hong Kong.

# Company Summary: EOS Inc.

## Business Overview
- **Type of Business:** Distributor of consumer products, primarily focusing on nutritional supplements and related health products.
- **Core Product:** Ginsenoside supplements branded as **“Bodywafer”**, specially manufactured by Wellhead Biological Technology Corp. in Taiwan, utilizing patented enzymatic technology to extract high-value ginsenosides for health and stamina enhancement.
- **Operations:** 
  - Sells products directly to channel partners across Asia including Taiwan, Hong Kong, Malaysia, Singapore, and other Southeast Asian countries.
  - Revenue sources mainly from sales in Taiwan and Hong Kong, with some sales in Southeast Asia.
- **Distribution Channels:** 
  - Distributors like Fortune King (HK) Trading Limited, Nine Trillion Science and Technology Media Co.
  - Small retailers and individual consumers in Southeast Asian markets.

## Corporate Structure
- **Incorporated:** Nevada, U.S.
- **Subsidiaries:**
  - Emperor Star International Trade Co., Ltd (Taiwan) — main operating subsidiary; engaged in marketing and distribution.
  - EOS International Inc. (British Virgin Islands) — holds interest in other subsidiaries but no current operations.
  - Shanghai Maosong Co., Ltd (China) — holds an 83.33% controlling interest; no active operations, but potential and legal risk exists due to PRC laws.

## Financial Data (2023)
- **Revenue:** $296,852 (decreased by 55% from $652,547 in 2022)
- **Net Loss:** $631,936 (improved from a net loss of $1,912,159 in 2022)
- **Employees:** 9 full-time employees (as of March 27, 2024)
- **Cash and Cash Equivalents:** $14,307 (as of December 31, 2023)
- **Total Current Assets:** $487,319
- **Total Current Liabilities:** $1,494,230
- **Working Deficit:** $1,006,911 (2023)

## Operational and Market Details
- Relies heavily on third-party manufacturers, especially Wellhead in Taiwan, for product sourcing.
- Faces competition from larger entities with greater resources.
- Focuses on expanding into first-tier cities in China and Southeast Asian online markets.
- No material current legal proceedings or ongoing litigation.
- Has a small, non-independent Board of Directors, with no independent directors.

## Risks & Strategic Considerations
- Significant dependence on key suppliers and channel partners.
- Conducts operations in jurisdictions with complex legal frameworks, especially China and Hong Kong, affecting enforceability of judgments and regulatory compliance.
- The company’s auditors have issued a “going concern” opinion due to financial losses and negative working capital, indicating uncertainty about future viability without further capital infusion or revenue growth.

---

*This summary provides a detailed overview based solely on the information given, without any assumptions or projections.*

EOS Inc. specializes in the marketing and distribution of ginsenoside nutritional supplements with a growing international presence.

# EOS Inc. Company Overview

## General Information
- **Incorporation**: April 3, 2015, in Nevada, USA
- **Subsidiaries**
  - **EOS INC. TAIWAN BRANCH** (100% owned)
  - **Emperor Star International Trade Co., Ltd.** (83% owned, originally acquired as a wholly-owned subsidiary)
  - **EOS International Inc. (EOS(BVI))** (100% owned, incorporated in the British Virgin Islands)
  - **Shanghai Maosong Co., Ltd.** (wholly owned subsidiary of EOS(BVI))
  
## Business Operations
EOS Inc. specializes in the **marketing and distribution** of nutritional supplements and related products, primarily focusing on ginsenoside supplements under the brand name **“Bodywafer.”**

### Key Products
- **Ginsenoside Supplements**: Exclusively manufactured by **Wellhead Biological Technology Corp.** in Taiwan, utilizing patented enzymatic technology for extraction.
- **Product Types**: Includes nutritional supplements and skin care products distributed across Asia.

### Customer Base
- **Main Markets**: Taiwan, Hong Kong, Singapore, Malaysia, and the People's Republic of China (PRC).
- **Distribution Channels**: Products are sold through:
  - Major distributors (e.g., Fortune King (HK) Trading Limited, Nine Trillion Science and Technology Media Co.)
  - Brick-and-mortar stores and online platforms
  - Direct sales to small retailers and individual customers in Southeast Asia.

### Sales and Marketing
- **Sales Staff**: 9 full-time employees (as of March 27, 2024).
- **Customer Engagement**: Sales training provided via onsite seminars and online webinars.

## Financial Information
- **Authorized Common Stock**: Increased to **1 billion shares** as of December 1, 2023.
- **Estimated Market Growth**: The nutritional food market was valued at **$136.2 billion** in 2020 and is expected to grow to **$204.7 billion** by 2026, indicating significant growth potential in the sector.

### Revenue and Income
- **Current Revenue**: Not specifically disclosed in the report.
- **Income**: Not specifically detailed, though the company is operationally active and marketing various products.

## Risk Factors
- **Third-Party Manufacturing Risks**: Reliance on third-party manufacturers poses challenges in terms of production control and supply chain.
- **Market Entry Difficulties**: Competitors with greater resources may hinder market penetration.
- **Regulatory Compliance**: Challenges in maintaining compliance with diverse and rapidly changing regulations across regions.

## Facilities
- **Office Location**: 2F., No. 157, Sec. 2, Nanjing E. Rd., Zhongshan Dist., Taipei City 104075, Taiwan. 
- **Lease**: Recent office lease commenced on December 1, 2023, for approximately **$2,293 per month**.

## Legal Standing
- No ongoing litigation or legal proceedings that could materially affect financial conditions have been reported. 

### Conclusion
EOS Inc. is an active player in the nutritional supplements market, focusing on ginsenoside products. With a robust distribution network and growing international presence, the company is positioned to capitalize on the expanding market while navigating the associated risks and challenges in its operations.

EOS INC.

10-K / April 2, 2025

10-K / August 6, 2024

10-K / April 2, 2025

Company Summary: EOS Inc.

Business Overview

Corporate Structure

Financial Data (2023)

Operational and Market Details

Risks & Strategic Considerations